Daniel S. Whittaker

Daniel S. Whittaker

Auto-generated profile, based on publicly available information

Daniel S. Whittaker

Department of Neuroscience, University of California San Diego; La Jolla, United States

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2018 in eneuro
Verified
Journal Article
Open access
PDF file
HWHuei-Bin Wang
Huei-Bin Wang
DLDawn H. Loh
Dawn H. Loh
DWDaniel S. Whittaker
Daniel S. Whittaker
TCTamara Cutler
Tamara Cutler
DHDavid Howland
David Howland
CCChristopher Colwell
Christopher Colwell
Huntington’s disease (HD) patients suffer from a progressive neurodegeneration that results in cognitive, psychiatric, cardiovascular and motor dysfunction. Disturbances in sleep/wake cycles are common among HD patients with reports of delayed sleep onset, frequent bedtime awakenings, and fatigue during the day. The heterozygous Q175 mouse model of HD has been shown to phenocopy many HD core symptoms including circadian dysfunctions. Because circadian dysfunction manifests early in the disease in both patients and mouse models, we sought to determine if early intervention that improve circadian rhythmicity can benefit HD and delay disease progression. We determined the effects of time-restricted feeding (TRF) on the Q175 mouse model. At 6 months of age, the animals were divided into two groups: ad lib and TRF. The TRF-treated Q175 mice were exposed to a 6-hr feeding/18-hr fasting regimen that was designed to be aligned with the middle of the time when mice are normally active. After 3 months of treatment (when mice reached the early disease stage), the TRF-treated Q175 mice showed improvements in their locomotor activity rhythm and sleep awakening time. Furthermore, we found improved heart rate variability (HRV), suggesting that their autonomic nervous system dysfunction was improved. Importantly, treated Q175 mice exhibited improved motor performance compared to untreated Q175 controls, and the motor improvements were correlated with improved circadian output. Finally, we found that the expression of several HD-relevant markers were restored to WT levels in the striatum of the treated mice using NanoString gene expression assays. Significance Statement HD is a genetically caused disease with no known cure. Lifestyle changes that not only improve the quality of life but also delay disease progression for HD patients are greatly needed. In this study, we found that time restricted feeding (TRF) improves activity/rest rhythms in the Q175 mouse model of HD. This treatment also improved motor performance and heart rate variability in the HD mice. Finally, TRF altered the expression of HD relevant markers in the striatum. Our study demonstrates the therapeutic potential of circadian-based treatment strategies in a pre-clinical model of HD.

5 September 2012 in Aging Cell
Verified
Journal Article
Open access
PDF file
GSGiuseppina Samengo
Giuseppina Samengo
AAAnna Avik
Anna Avik
BFBrian Fedor
Brian Fedor
DWDaniel Whittaker
Daniel Whittaker
KMKyu H. Myung
Kyu H. Myung
JTJames G. Tidball
James G. Tidball
Summary: Sarcopenia, the age‐related loss of muscle mass, is a highly‐debilitating consequence of aging. In this investigation, we show sarcopenia is greatly reduced by muscle‐specific overexpression of calpastatin, the endogenous inhibitor of calcium‐dependent proteases (calpains). Further, we show that calpain cleavage of specific structural and regulatory proteins in myofibrils is prevented by covalent modification of calpain by nitric oxide (NO) throughS‐nitrosylation. We find that calpain in adult, non‐sarcopenic muscles isS‐nitrosylated but that aging leads to loss ofS‐nitrosylation, suggesting that reducedS‐nitrosylation during aging leads to increased calpain‐mediated proteolysis of myofibrils. Further, our data show that muscle aging is accompanied by loss of neuronal nitric oxide synthase (nNOS), the primary source of muscle NO, and that expression of a muscle‐specificnNOStransgene restores calpainS‐nitrosylation in aging muscle and prevents sarcopenia. Together, the findings show thatin vivoreduction of calpainS‐nitrosylation in muscle may be an important component of sarcopenia, indicating that modulation of NO can provide a therapeutic strategy to slow muscle loss during old age.

7 August 2018 in Journal of Biological Rhythms
Verified
Journal Article
Closed access
DWDaniel S. Whittaker
Daniel S. Whittaker
DLDawn H. Loh
Dawn H. Loh
HWHuei-Bin Wang
Huei-Bin Wang
YTYu Tahara
Yu Tahara
DKDika Kuljis
Dika Kuljis
CCChristopher Colwell
Christopher Colwell
Huntington’s disease (HD) patients suffer from progressive neurodegeneration that results in cognitive, psychiatric, cardiovascular, and motor dysfunction. Disturbances in sleep-wake cycles are common among HD patients with reports of delayed sleep onset, frequent bedtime awakenings, and excessive fatigue. The BACHD mouse model exhibits many HD core symptoms including circadian dysfunction. Because circadian dysfunction manifests early in the disease in both patients and mouse models, we sought to determine if early interventions that improve circadian rhythmicity could benefit HD symptoms and delay disease progression. We evaluated the effects of time-restricted feeding (TRF) on the BACHD mouse model. At 3 months of age, the animals were divided into 2 groups: ad lib and TRF. The TRF-treated BACHD mice were exposed to a 6-h feeding/18-h fasting regimen that was designed to be aligned with the middle (ZT 15-21) of the period when mice are normally active (ZT 12-24). Following 3 months of treatment (when mice reached the early disease stage), the TRF-treated BACHD mice showed improvements in their locomotor activity and sleep behavioral rhythms. Furthermore, we found improved heart rate variability, suggesting that their autonomic nervous system dysfunction was improved. On a molecular level, TRF altered the phase but not the amplitude of the PER2::LUC rhythms measured in vivo and in vitro. Importantly, treated BACHD mice exhibited improved motor performance compared with untreated BACHD controls, and the motor improvements were correlated with improved circadian output. It is worth emphasizing that HD is a genetically caused disease with no known cure. Lifestyle changes that not only improve the quality of life but also delay disease progression for HD patients are greatly needed. Our study demonstrates the therapeutic potential of circadian-based treatment strategies in a preclinical model of HD.

1 April 2020 in Kidney International
Verified
Journal Article
Closed access
HMHiroaki Motohashi
Hiroaki Motohashi
YTYu Tahara
Yu Tahara
DWDaniel S. Whittaker
Daniel S. Whittaker
HWHuei-Bin Wang
Huei-Bin Wang
TYTakahiro Yamaji
Takahiro Yamaji
SSShigenobu Shibata
Shigenobu Shibata

1 January 2017 in Neurobiology of Sleep and Circadian Rhythms
Verified
Journal Article
Open access
HWHuei-Bin Wang
Huei-Bin Wang
DWDaniel S. Whittaker
Daniel S. Whittaker
DTDanny Truong
Danny Truong
AMAly K. Mulji
Aly K. Mulji
CGCristina A Ghiani
Cristina A Ghiani
CCChristopher Colwell
Christopher Colwell
Patients with Huntington's disease (HD) exhibit movement disorders, psychiatric disturbance and cognitive impairments as the disease progresses. Abnormal sleep/wake cycles are common among HD patients with reports of delayed sleep onset, fatigue during the day, and a delayed pattern of melatonin secretion all of which suggest circadian dysfunction. Mouse models of HD confirm disrupted circadian rhythms with pathophysiology found in the central circadian clock (suprachiasmatic nucleus). Importantly, circadian dysfunction manifests early in disease, even before the classic motor symptoms, in both patients and mouse models. Therefore, we hypothesize that the circadian dysfunction may interact with the disease pathology and exacerbate the HD symptoms. If correct, early intervention may benefit patients and delay disease progression. One test of this hypothesis is to determine whether light therapy designed to strengthen this intrinsic timing system can delay the disease progression in mouse models. Therefore, we determined the impact of blue wavelength-enriched light on two HD models: the BACHD and Q175 mice. Both models received 6 h of blue-light at the beginning of their daily light cycle for 3 months. After treatment, both genotypes showed improvements in their locomotor activity rhythm without significant change to their sleep behavior. Critically, treated mice of both lines exhibited improved motor performance compared to untreated controls. Focusing on the Q175 genotype, we sought to determine whether the treatment altered signaling pathways in brain regions known to be impacted by HD using NanoString gene expression assays. We found that the expression of several HD relevant markers was altered in the striatum and cortex of the treated mice. Our study demonstrates that strengthening the circadian system can delay the progression of HD in pre-clinical models. This work suggests that lighting conditions should be considered when managing treatment of HD and other neurodegenerative disorders.

15 November 2018 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
FLFrank Y. Lee
Frank Y. Lee
HWHuei-Bin Wang
Huei-Bin Wang
OHOlivia N. Hitchcock
Olivia N. Hitchcock
DLDawn Hsiao Loh
Dawn Hsiao Loh
DWDaniel S. Whittaker
Daniel S. Whittaker
CGCristina A Ghiani
Cristina A Ghiani
Mice lacking a functional Biogenesis of Lysosome-related Organelles Complex 1 (BLOC-1), such as those of the pallid line, display cognitive and behavioural impairments reminiscent of those presented by individuals with intellectual and developmental disabilities. Although disturbances in the sleep/wake cycle are commonly lamented by these individuals, the underlying mechanisms, including the possible role of the circadian timing system, are still unknown. In this paper, we have explored sleep/circadian malfunctions and underlying mechanisms in BLOC-1-deficient pallid mice. These mutants exhibited less sleep behaviour in the beginning of the resting phase than wild-type mice with a more broken sleeping pattern in normal light-dark conditions. Furthermore, the strength of the activity rhythms in the mutants were reduced with significantly more fragmentation and lower precision than in age-matched controls. These symptoms were accompanied by an abnormal preference for the open arm in the elevated plus maze in the day and poor performance in the novel object recognition at night. At the level of the central circadian clock (the suprachiasmatic nucleus, SCN), loss of BLOC-1 caused subtle morphological changes including a larger SCN and increased expression of the relative levels of the clock gene Per2 product during the day but did not affect the neuronal activity rhythms. In the hippocampus, the pallid mice presented with anomalies in the cytoarchitecture of the Dentate Gyrus granule cells, but not in CA1 pyramidal neurones, along with altered PER2 protein levels as well as reduced pCREB/tCREB ratio during the day. Our findings suggest that lack of BLOC-1 in mice disrupts the sleep/wake cycle and performance in behavioural tests associated with specific alterations in cytoarchitecture and protein expression.